JAMA Network Open study catalogs adverse effects from nonapproved retatrutide use

The wire

1. 01The cross-sectional study by Sehgal, Tronieri, Rader and colleagues evaluates self-reported adverse effects among social media users who described taking nonapproved retatrutide.
2. 02Retatrutide remains investigational, yet research-chemical vendors sell it; clinicians and telehealth operators are increasingly fielding patients already dosing themselves outside any trial.
3. 03Self-reported social media data cannot confirm product identity, dose or causality, and the posts are not a representative sample of users.

From the source

Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide

JAMA network open · 2026 Oct 1 · Sehgal NKR, Tronieri JS, Rader B et al.